TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Dec 14, 2021--BostonGene Corporation and NEC Corporation (NEC; TSE: 6701) today announced a strategic global partnership agreement that will enable the companies to offer BostonGene Tumor Portrait TM Tests in key international markets, including Japan as the first market outside of the U.S. BostonGene Tumor Portrait™ Tests, based on integrated genomic and transcriptomic analysis, propel precision medicine into daily clinical practice and support physicians in actualizing personalized therapy for cancer patients. Going forward, the two companies will jointly develop the market for BostonGene Tumor Portrait™ Tests globally. “Partnering with NEC will allow BostonGene to expedite our international expansion which aims to improve the standard of care for cancer patients around the world.”This agreement expands upon existing collaborations between BostonGene and NEC. Through these comprehensive analyses, BostonGene Tumor Portrait TM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient.

Source: thestar December 14, 2021 14:58 UTC